229 related articles for article (PubMed ID: 15558012)
1. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
3. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
4. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
[TBL] [Abstract][Full Text] [Related]
5. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
6. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
7. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression.
Saegusa M; Machida D; Okayasu I
Br J Cancer; 2000 Feb; 82(3):571-8. PubMed ID: 10682668
[TBL] [Abstract][Full Text] [Related]
8. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.
Schindl M; Schoppmann SF; Ströbel T; Heinzl H; Leisser C; Horvat R; Birner P
Clin Cancer Res; 2003 Feb; 9(2):779-85. PubMed ID: 12576450
[TBL] [Abstract][Full Text] [Related]
9. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
11. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
De Meyer T; Bijsmans IT; Van de Vijver KK; Bekaert S; Oosting J; Van Criekinge W; van Engeland M; Sieben NL
J Pathol; 2009 Jan; 217(1):14-20. PubMed ID: 18991331
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
13. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma.
Shigemasa K; Gu L; O'Brien TJ; Ohama K
Clin Cancer Res; 2003 May; 9(5):1756-63. PubMed ID: 12738731
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
15. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
16. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
17. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
Schwartz DR; Kardia SL; Shedden KA; Kuick R; Michailidis G; Taylor JM; Misek DE; Wu R; Zhai Y; Darrah DM; Reed H; Ellenson LH; Giordano TJ; Fearon ER; Hanash SM; Cho KR
Cancer Res; 2002 Aug; 62(16):4722-9. PubMed ID: 12183431
[TBL] [Abstract][Full Text] [Related]
18. Analysis of gene expression in early-stage ovarian cancer.
Marchini S; Mariani P; Chiorino G; Marrazzo E; Bonomi R; Fruscio R; Clivio L; Garbi A; Torri V; Cinquini M; Dell'Anna T; Apolone G; Broggini M; D'Incalci M
Clin Cancer Res; 2008 Dec; 14(23):7850-60. PubMed ID: 19047114
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.
Warrenfeltz S; Pavlik S; Datta S; Kraemer ET; Benigno B; McDonald JF
Mol Cancer; 2004 Oct; 3():27. PubMed ID: 15471544
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.
Jazaeri AA; Lu K; Schmandt R; Harris CP; Rao PH; Sotiriou C; Chandramouli GV; Gershenson DM; Liu ET
Mol Carcinog; 2003 Feb; 36(2):53-9. PubMed ID: 12557260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
